新型P2Y12受体抑制剂替格瑞洛临床研究进展

摘要/Abstract

摘要： 抗血小板药物是冠心病治疗的基石,对防治心肌缺血和介入并发症是有益的。目前治疗冠心病和经皮冠状动脉介入治疗(percutaneous coronary intervention, PCI)指南推荐使用的口服抗血小板药物包括氯吡格雷、替格瑞洛、普拉格雷联合阿司匹林双重抗血小板治疗预防复发性缺血事件。本文对新型P2Y12受体抑制剂替格瑞洛的药代动力学和药效学特点以及在冠心病患者中的临床研究结果作一介绍。

关键词: 急性冠脉综合征, 替格瑞洛, 氯吡格雷, 抗血小板药物, 经皮冠状动脉介入治疗

Abstract: Antiplatelet drug is the cornerstone for CHD (coronary heart disease) treatment, which is beneficial to the myocardial ischemia prevention and treatment as well complication intervention. At present, the CHD (coronary heart disease) and PCI (percutaneous coronary intervention) treatment manual recommends to use oral antiplatelet drugs including clopidogrel, ticagrelor, trasugrel together with aspirin dual antiplatelet therapy for recurrent ischemic events prevention. This article introduces the pharmacokinetics and pharmacodynamics features of new type P2Y12 receptor inhibitor ticagrelor, as well as evidence-based medical evidence in patients with coronary artery disease.

Key words: acute coronary syndrome, ticagrelor, clopidogrel, antiplatelet, percutaneous coronary intervention

中图分类号:

R541.4

章霞, 柯永胜. 新型P2Y12受体抑制剂替格瑞洛临床研究进展[J]. 中国临床药理学与治疗学, 2014, 19(4): 459-464.

ZHANG Xia, KE Yong-sheng. Clinical research of new type P2Y12 Receptor inhibitor ticagrelor[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(4): 459-464.

参考文献

[1] World Health Organization. Top ten causes of death. Geneva: World Health Organization; 2011.Available from:http://www.who.int/ mediacentre/factsheets/fs310_2008.pdf.Accessed December 14,2012.
[2] Behan MW, Chew DP, Aylward PE. The role of antiplatelet therapy in the secondary prevention of coronary artery disease[J]. Curr Opin Cardiol, 2010, 25(4): 321-328.
[3] Marczewski MM, Postula M, Kosior D. Novel antiplatelet agents in the prevention of cardiovascular complications-focus on ticagrelor[J]. Vasc Health Risk Manag, 2010, 6: 419-429.
[4] Siller-Matula JM, Krumphuber J, Jilma B. Pharmacokinetic,pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases[J]. Br J Pharmacol, 2010, 159(3): 502-517.
[5] Zhou D, Andersson TB, Grimm SW. In vitro evaluation of potential drug-drug interactions with ticagrelor:cytochrome P450 reaction phenotyping,inhibition,induction,and differential kinetics[J]. Drug Metab Dispos, 2011, 39(4): 703-710.
[6] Teng R, Oliver S, Hayes MA. Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects[J]. Drug Metab Dispos, 2010, 38(9): 1514-1521.
[7] Teng R, Butler K. Pharmacokinetics,pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor,a reversibly binding oral P2Y12 receptor antagonist in healthy subjects[J]. Eur J Clin Pharmacol, 2010, 66(5): 487-496.
[8] Gurbel PA, Bliden KP, Butler K, et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies:the RESPOND study[J]. Circulation, 2010, 121(10): 1188-1199.
[9] Husted S, Emanuelsson H, Hepinstall S, et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin[J]. Eur Heart J, 2006, 27(9): 1038-1047.
[10] Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary disease: the ONSET/ OFFSET study[J]. Circulation, 2009, 120(25): 2577-2585.
[11] Storey RF, Angiolillo DJ, Patil SB, et al. Inhibitor effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (Platelet Inhibitiona and Patient Outcomes) PLATELET substudy[J]. J Am Coll Cardiol, 2010, 56(18): 1456-1462.
[12] Butler K, Teng R. Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers[J]. Br J Clin Pharmacol, 2010, 70(1): 65-77.
[13] Teng R, Mitchell PD, Butler K. Lack of significant food effect on the pharmacokinetics of ticagrelor in healthy volunteers[J]. J Clin Pharm Ther, 2012, 37(4): 464-468.
[14] Butler K, Teng R. Pharmacokinetics, pharmacodynamics, and safety of ticagrelor in volunteers with severe renal impairment[J]. J Clin Pharmacol, 2012, 52(9): 1388-1398.
[15] University of Patras. Ticagrelor in clopidogrel resistant patients undergoing chronic hemodialysis. In: ClinicalTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2012 [updated February 2, 2012]. Available from: http://clinicaltrials. gov/show/NCT01511471. NLM identifer: NCT01511471. Accessed December 14, 2012.
[16] Butler K, Teng R. Pharmacokinetics, pharmacodynamics, and safety of ticagrelor in volunteers with mild hepatic impairment[J]. J Clin Pharmacol, 2011, 51(7): 978-987.
[17] Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes[J]. N Engl J Med, 2009, 361(11): 1045-1057.
[18] Storey RF, Husted S, Harrington RA, et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes[J]. J Am Coll Cardiol, 2007, 50(19): 1852-1856.
[19] Alexopoulos D, Galati A, Xanthopoulou I, et al. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study[J]. J Am Coll Cardiol, 2012, 60(3): 193-199.
[20] Bonello L, Tantry US, Marcucci R, et al. Consenus and future directions on the defnition of high on-treatment platelet reactivity to adenosine diphosphate[J]. J Am Coll Cardiol, 2010, 56(12): 919-933.
[21] Cannon CP, Husted S, Harrington RA, et al. Safety, tolerability, and initial effcacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist,compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial[J]. J Am Coll Cardiol, 2007, 50(19): 1844-1851.
[22] Center for Drug Evaluation and Research. Ticagrelor: Complete Response Review Addenum. Silver Spring, MD: US Food and Drug Administration; 2011. Available from: http://www. accessdata.fda.gov/drugsatfda_docs/nda/2011/022433Orig1s000MedR.pdf. Accessed January 5, 2013.
[23] Cannon CP, Harrington RA, James S, et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomized double-blind study[J]. Lancet, 2010, 375(9711): 283-293.
[24] Steg PG, James S, Harrington RA, et al. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention:a Platelet Inhibition and Patient Outcomes(PLATO) trial subgroup analysis[J]. Circulation, 2010, 122(21): 2131-2141.
[25] Held C, Asenblad N, Bassand JP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery:results from the PLATO (Platelet Inhibition and Patient Outcomes) triaal[J]. J Am Coll Cardiol, 2011, 57(6): 672-684.
[26] Varenhorst C, Alstrom U, Scirica B, et al. Fctors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery[J]. J Am Coll Cardiol, 2012, 60(17): 1623-1630.
[27] James S, Budaj A, Aylward P, et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial[J]. Circulation, 2010, 122(11): 1056-1067.
[28] James S, Angiolillo DJ, Cornel JH, et al. Ticagrelor vs clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the Platelet Inhibition and Patient Outcomes (PLATO) trial[J]. Eur Heart J, 2010, 31(24): 3006-3016.
[29] James SK, Storey RF, Khurmi NS, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack[J]. Circulation, 2012, 125(23), 2914-2921.
[30] Husted S, James S, Becker RC, et al. Ticagrelor verss uclopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized Platelet Inhibition and Patient Outcomes (PLATO) trial[J]. Circ Cardiovasc Qual Outcomes, 2012, 5(5): 680-688.
[31] Dinicolantonio JJ, Serebruany VL. Exploring the reduction in myocardial infarctions in the PLATO trial: which patients benefited on ticagrelor VS clopidogrel[J] ? Int J Cardial, 2013, 123: 451-456.